Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure

Eric B. Stanton, Mark S. Hansen, Michael J. Sole, Yehia Gawad, Milton Packer, Bertram Pitt, Karl Swedberg, Jean L. Rouleau

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Cardiac troponin I (cTnI) has been validated as a sensitive and specific market of myocyte damage, and is elevated in some patients with congestive heart failure. Objective: To assess the relationship between elevated levels of cTnI and survival in stable patients with congestive heart failure. Patients and methods: It was assessed whether detectable serial levels of cTnI were associated with mortality in 211 patients with stable, severe heart failure at entry and one month into the Prospective Randomized Flosequinan Longevity Evaluation (PROFILE) study. Of these patients, 66 also had measurements taken at 12 months. Results: Patients were New York Heart Association (NYHA) class III (n=197) or IV (n=14), with a baseline left ventricular ejection fraction of 22±7% (range 8% to 35%). Patients with a detectable level of cTnI at one month had an increased mortality (OR 2.608 [95% CI 1.061 to 6.409]; P=0.037). The association between mortality and detectable cTnI levels at baseline or 12 months did not reach statistical significance. Patients with a cTnI level that rose or remained elevated between baseline and one month had a higher mortality rate (50%) than those in whom the cTnI level fell (9%) between baseline and one month (P=0.025). In a multivariate model of survival that included sex, treatment, age, left ventricular ejection fraction, NYHA class and creatinine, only detectable levels of cTnI at one month were associated with survival (P=0.037). Conclusions: cTnI is released in stable, chronic heart failure and is associated with a poor prognosis, independent of other important risk factors. The risk is particularly elevated when detectable cTnI levels rise or remain elevated over time.

Original languageEnglish (US)
Pages (from-to)39-43
Number of pages5
JournalCanadian Journal of Cardiology
Volume21
Issue number1
StatePublished - Jan 2005

Fingerprint

Troponin I
Heart Failure
Survival
flosequinan
Mortality
Stroke Volume
Muscle Cells
Creatinine

Keywords

  • Flosequinan
  • Heart failure
  • Survival
  • Troponin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Stanton, E. B., Hansen, M. S., Sole, M. J., Gawad, Y., Packer, M., Pitt, B., ... Rouleau, J. L. (2005). Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. Canadian Journal of Cardiology, 21(1), 39-43.

Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. / Stanton, Eric B.; Hansen, Mark S.; Sole, Michael J.; Gawad, Yehia; Packer, Milton; Pitt, Bertram; Swedberg, Karl; Rouleau, Jean L.

In: Canadian Journal of Cardiology, Vol. 21, No. 1, 01.2005, p. 39-43.

Research output: Contribution to journalArticle

Stanton, EB, Hansen, MS, Sole, MJ, Gawad, Y, Packer, M, Pitt, B, Swedberg, K & Rouleau, JL 2005, 'Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure', Canadian Journal of Cardiology, vol. 21, no. 1, pp. 39-43.
Stanton EB, Hansen MS, Sole MJ, Gawad Y, Packer M, Pitt B et al. Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. Canadian Journal of Cardiology. 2005 Jan;21(1):39-43.
Stanton, Eric B. ; Hansen, Mark S. ; Sole, Michael J. ; Gawad, Yehia ; Packer, Milton ; Pitt, Bertram ; Swedberg, Karl ; Rouleau, Jean L. / Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. In: Canadian Journal of Cardiology. 2005 ; Vol. 21, No. 1. pp. 39-43.
@article{7368f321a95640588fa25172ec6e6ddb,
title = "Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure",
abstract = "Background: Cardiac troponin I (cTnI) has been validated as a sensitive and specific market of myocyte damage, and is elevated in some patients with congestive heart failure. Objective: To assess the relationship between elevated levels of cTnI and survival in stable patients with congestive heart failure. Patients and methods: It was assessed whether detectable serial levels of cTnI were associated with mortality in 211 patients with stable, severe heart failure at entry and one month into the Prospective Randomized Flosequinan Longevity Evaluation (PROFILE) study. Of these patients, 66 also had measurements taken at 12 months. Results: Patients were New York Heart Association (NYHA) class III (n=197) or IV (n=14), with a baseline left ventricular ejection fraction of 22±7{\%} (range 8{\%} to 35{\%}). Patients with a detectable level of cTnI at one month had an increased mortality (OR 2.608 [95{\%} CI 1.061 to 6.409]; P=0.037). The association between mortality and detectable cTnI levels at baseline or 12 months did not reach statistical significance. Patients with a cTnI level that rose or remained elevated between baseline and one month had a higher mortality rate (50{\%}) than those in whom the cTnI level fell (9{\%}) between baseline and one month (P=0.025). In a multivariate model of survival that included sex, treatment, age, left ventricular ejection fraction, NYHA class and creatinine, only detectable levels of cTnI at one month were associated with survival (P=0.037). Conclusions: cTnI is released in stable, chronic heart failure and is associated with a poor prognosis, independent of other important risk factors. The risk is particularly elevated when detectable cTnI levels rise or remain elevated over time.",
keywords = "Flosequinan, Heart failure, Survival, Troponin",
author = "Stanton, {Eric B.} and Hansen, {Mark S.} and Sole, {Michael J.} and Yehia Gawad and Milton Packer and Bertram Pitt and Karl Swedberg and Rouleau, {Jean L.}",
year = "2005",
month = "1",
language = "English (US)",
volume = "21",
pages = "39--43",
journal = "Canadian Journal of Cardiology",
issn = "0828-282X",
publisher = "Pulsus Group Inc.",
number = "1",

}

TY - JOUR

T1 - Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure

AU - Stanton, Eric B.

AU - Hansen, Mark S.

AU - Sole, Michael J.

AU - Gawad, Yehia

AU - Packer, Milton

AU - Pitt, Bertram

AU - Swedberg, Karl

AU - Rouleau, Jean L.

PY - 2005/1

Y1 - 2005/1

N2 - Background: Cardiac troponin I (cTnI) has been validated as a sensitive and specific market of myocyte damage, and is elevated in some patients with congestive heart failure. Objective: To assess the relationship between elevated levels of cTnI and survival in stable patients with congestive heart failure. Patients and methods: It was assessed whether detectable serial levels of cTnI were associated with mortality in 211 patients with stable, severe heart failure at entry and one month into the Prospective Randomized Flosequinan Longevity Evaluation (PROFILE) study. Of these patients, 66 also had measurements taken at 12 months. Results: Patients were New York Heart Association (NYHA) class III (n=197) or IV (n=14), with a baseline left ventricular ejection fraction of 22±7% (range 8% to 35%). Patients with a detectable level of cTnI at one month had an increased mortality (OR 2.608 [95% CI 1.061 to 6.409]; P=0.037). The association between mortality and detectable cTnI levels at baseline or 12 months did not reach statistical significance. Patients with a cTnI level that rose or remained elevated between baseline and one month had a higher mortality rate (50%) than those in whom the cTnI level fell (9%) between baseline and one month (P=0.025). In a multivariate model of survival that included sex, treatment, age, left ventricular ejection fraction, NYHA class and creatinine, only detectable levels of cTnI at one month were associated with survival (P=0.037). Conclusions: cTnI is released in stable, chronic heart failure and is associated with a poor prognosis, independent of other important risk factors. The risk is particularly elevated when detectable cTnI levels rise or remain elevated over time.

AB - Background: Cardiac troponin I (cTnI) has been validated as a sensitive and specific market of myocyte damage, and is elevated in some patients with congestive heart failure. Objective: To assess the relationship between elevated levels of cTnI and survival in stable patients with congestive heart failure. Patients and methods: It was assessed whether detectable serial levels of cTnI were associated with mortality in 211 patients with stable, severe heart failure at entry and one month into the Prospective Randomized Flosequinan Longevity Evaluation (PROFILE) study. Of these patients, 66 also had measurements taken at 12 months. Results: Patients were New York Heart Association (NYHA) class III (n=197) or IV (n=14), with a baseline left ventricular ejection fraction of 22±7% (range 8% to 35%). Patients with a detectable level of cTnI at one month had an increased mortality (OR 2.608 [95% CI 1.061 to 6.409]; P=0.037). The association between mortality and detectable cTnI levels at baseline or 12 months did not reach statistical significance. Patients with a cTnI level that rose or remained elevated between baseline and one month had a higher mortality rate (50%) than those in whom the cTnI level fell (9%) between baseline and one month (P=0.025). In a multivariate model of survival that included sex, treatment, age, left ventricular ejection fraction, NYHA class and creatinine, only detectable levels of cTnI at one month were associated with survival (P=0.037). Conclusions: cTnI is released in stable, chronic heart failure and is associated with a poor prognosis, independent of other important risk factors. The risk is particularly elevated when detectable cTnI levels rise or remain elevated over time.

KW - Flosequinan

KW - Heart failure

KW - Survival

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=15044359500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044359500&partnerID=8YFLogxK

M3 - Article

C2 - 15685301

AN - SCOPUS:15044359500

VL - 21

SP - 39

EP - 43

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

SN - 0828-282X

IS - 1

ER -